LYEL

Business Context and Reporting Period

Company: Lyell Immunopharma, Inc. (LYEL)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Lyell is a late-stage clinical cell therapy company developing autologous CAR T-cell therapies for hematologic malignancies and solid tumors. Its lead candidate, ronde-cel (CD19/CD20 dual-targeting), is in pivotal trials for large B-cell lymphoma (LBCL). In November 2025, the company acquired exclusive global rights (outside mainland China) to LYL273, a GCC-targeted CAR T-cell candidate for metastatic colorectal cancer (mCRC).

Key Financial Metrics

Note: Cash, Cash Equivalents & Marketable Securities excludes restricted cash of $1,586.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by $28.0 million (54%) primarily due to a $17.6 million non-cash gain from the settlement of a Securities Purchase Agreement (SPA) put/call instrument and reduced operating expenses.
• Operating Expense Decrease: Total operating expenses declined by $13.1 million. R&D expenses dropped $6.8 million due to lower personnel costs and reduced severance following the 2025 technology transfer of ronde-cel to the LyFE Manufacturing Center. G&A expenses fell $4.5 million, driven by lower headcount and stock-based compensation.
• Other Income Surge: Other income, net increased by $16.6 million to $17.9 million, almost entirely attributable to the fair value adjustment and settlement of the SPA put/call liability.
• Financing Activity: The company raised approximately $51.7 million in Q1 2026 through a milestone closing under the SPA ($50.0 million) and at-the-market (ATM) offerings ($1.7 million), compared to negligible financing in Q1 2025.

Guidance, Outlook, and Risks

• Clinical Outlook:
  • Ronde-cel: The PiNACLE pivotal trial (3L+ setting) is ongoing with data expected in H2 2026 and pivotal data in mid-2027. The PiNACLE-H2H Phase 3 head-to-head trial (2L setting) commenced dosing in February 2026.
  • LYL273: Dosing commenced at Dose Level 3 in March 2026. Safety data is expected in H1 2026, with clinical outcomes expected in H2 2026.
• Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($261.0 million excluding restricted cash) are sufficient to fund operations for at least the next 12 months. However, the company expects to incur significant losses for the foreseeable future and will require additional capital for commercialization and further development.
• Key Risks:
  • Capital Requirements: Failure to raise additional capital could force delays or termination of development programs.
  • Clinical Uncertainty: Interim data may not predict final results; clinical trials may fail to demonstrate safety or efficacy.
  • Manufacturing: Reliance on the LyFE Manufacturing Center and third-party suppliers introduces supply chain and quality control risks.
  • Regulatory: Novel cell therapies face heightened regulatory scrutiny; special designations (Fast Track, RMAT) do not guarantee approval.

Investor Verification Checklist

• Capital Runway: Verify the sufficiency of the $261 million cash position against the projected burn rate for the upcoming pivotal trials and potential commercialization costs.
• SPA Settlement Impact: Confirm the non-recurring nature of the $17.6 million gain and its effect on the reported net loss, ensuring it is excluded from core operational performance analysis.
• Clinical Milestones: Monitor enrollment rates and safety data for the PiNACLE-H2H and LYL273 trials, as these are critical for future valuation and funding.
• Contingent Liabilities: Review the terms of the ICT License Agreement and success payment obligations (Fred Hutch/Stanford) for potential future cash or equity outflows.
• Manufacturing Capacity: Assess the LyFE Manufacturing Center's ability to scale production for both ronde-cel and the newly acquired LYL273 without delays.